CARM | tickerfilter.com

Fundamental analysis

27%

Profitability 29%

Dept financing 17%

Liquidity 75%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-5.31%

1 Month

-0.93%

3 Months

-18.32%

6 Months

-58.04%

1 Year

-84.67%

2 Year

-92.13%

Key data

Stock price

$1.06

P/E Ratio

-0.61

DAY RANGE

$1.06 - N/A

EPS

-$1.77

52 WEEK RANGE

$0.80 - $6.12

52 WEEK CHANGE

-$0.83

MARKET CAP

44.453 M

YIELD

N/A

SHARES OUTSTANDING

41.545 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/07/2024

BETA

2.27

PUBLIC FLOAT

AVERAGE 10 VOLUME

$117,024

AVERAGE 30 VOLUME

$181,340

Company detail

CEO: Thomas Cannell
Region: US
Website: http://www.elevenbio.com/
Employees: 35
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

eleven biotherapeutics is focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics to improve human health and treat disease. eleven biotherapeutics' scientists are engineering protein-based drugs using newly available structural information and the company’s unique molecular understanding of clinical effects to create the next generation of protein-based medicines to treat important diseases with unmet needs, such as inflammatory conditions and coagulation disorders.

CARM - Carisma Therapeutics Inc